Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 1, 2025Clinical and Translational MedicineOpen Access

Gene‐specific ctDNA dynamics predict tumour burden and survival outcomes in ESCC: A prospective cohort study

View Full Paper
Ask AI
Bookmark
Share

Authors

RGRentong GuTLTao LiuWCWen Cheng

Discussion

Loading...

Member takes

Overview

Prospective cohort study shows ctDNA mutations correlate with tumour burden in ESCC, suggesting personalized treatment strategies.

Key Points

  • Postoperative tp53 ctDNA positivity predicts worse disease-free survival and overall survival outcomes in esophageal squamous cell carcinoma.
  • Preoperative ctDNA mutations were found in 96.3% of patients, with tp53 being the most prevalent mutation detected in 59.3% of cases.
  • This prospective cohort study evaluated preoperative and postoperative ctDNA dynamics in 54 treatment-naïve ESCC patients undergoing radical surgery.
  • Preoperative ptent positivity serves as a strong independent prognostic factor for worse clinical outcomes, highlighting its potential in personalized treatment.

Cite This Study

Gu et al. (2025) studied this question.

synapsesocial.com/papers/68af2b68cf1dd9ea359e4d31https://doi.org/10.1002/ctm2.70446
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Circulating tumor DNA as a marker of molecular residual disease in resected esophageal squamous cell carcinoma2025
  2. 2142. PREDICTIVE ROLE OF CTDNA IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA RECEIVING NEOADJUVANT IMMUNOTHERAPY AND CHEMOTHERAPY: A PROSPECTIVE COHORT STUDY2025
  3. 3353. PROGNOSTIC VALUE OF CIRCULATING TUMOR DNA IN THE PERIOPERATIVE MANAGEMENT OF ESOPHAGEAL CANCER2025
  4. 4290. OPTIMIZING ESOPHAGEAL CANCER TREATMENT: PERSONALIZED CTDNA IMPROVES RESIDUAL DISEASE DETECTION AFTER NEOADJUVANT CHEMORADIOTHERAPY AND GUIDES ADAPTIVE ADJUVANT IMMUNOTHERAPY2025
  5. 5ctDNA detects residual disease after neoadjuvant chemoradiotherapy and guides adjuvant therapy in esophageal squamous cell carcinoma2025